Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.

Patients treated in Respiratory Intensive Care Units for COVID-19 are more likely to get mood disorders than those in other care settings.

Breathing in newborn rats is affected differently by hormones based on their sex.

Exposure to Corexit dispersants during the oil spill cleanup was linked to increased respiratory and eye irritation symptoms in workers.

Myoepithelial cells can repair airways after severe injury.

A woman died from cancer that spread from a long-standing cyst on her abdomen.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

A woman with X-linked chronic granulomatous disease developed lupus-like skin lesions, improved with treatment, suggesting a unique skin condition in carriers.

Children under 18 had milder SARS with no deaths, but teenagers faced higher severe illness risk, and effective treatments were uncertain.

Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.

COVID-19 may cause temporary hair loss in some people.

Oxidative stress plays a significant role in vitiligo, and both skin and non-skin cells may be involved.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Tofacitinib is an effective and safe treatment for alopecia areata.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Women with PCOS are much more likely to have sleep problems and should be checked for them.

About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.

Children generally have milder SARS symptoms than adults, with good outcomes and no deaths reported, but long-term effects are unclear.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

A child on life support experienced rapid hair loss due to severe illness affecting hair growth.

Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.

Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

People with alopecia areata may also have allergic rhinitis and should be checked for respiratory allergies.